Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Novel use of a CLIA-certified CDKN2C loss assay in sporadic medullary thyroid carcinoma.

Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EG.

Surgery. 2019 Oct 21. pii: S0039-6060(19)30564-1. doi: 10.1016/j.surg.2019.03.041. [Epub ahead of print]

PMID:
31648931
2.

Dual Time-Point 18F-FDG PET/CT in Spinal Sarcoidosis: A Single Institution Case Series.

Ordóñez-Rubiano EG, Solano-Noguera DF, Row W, Weinberg J, Tatsui CE, Johnson JM, Gule-Monroe MK.

Spine (Phila Pa 1976). 2019 Nov 1;44(21):E1248-E1255. doi: 10.1097/BRS.0000000000003122.

PMID:
31634300
3.

Diagnostic Accuracy and Scope of Intraoperative Transoral Ultrasound and Transoral Ultrasound-Guided Fine-Needle Aspiration of Retropharyngeal Masses.

Vu TH, Kwon M, Ahmed S, Gule-Monroe M, Chen MM, Sun J, Fornage BD, Debnam JM, Edeiken-Monroe B.

AJNR Am J Neuroradiol. 2019 Nov;40(11):1960-1964. doi: 10.3174/ajnr.A6236. Epub 2019 Oct 3.

PMID:
31582388
4.

Utility of subcategorization of atypia of undetermined significance/follicular lesion of undetermined significance category in ultrasound-guided thyroid fine-needle aspiration in a large referral cancer center.

Gan Q, Edeiken BS, Chen MM, Grubbs EG, Busaidy NL, Zafereo M, Perrier ND, Gule-Monroe MD, Krishnamurthy S.

J Am Soc Cytopathol. 2019 Nov - Dec;8(6):309-316. doi: 10.1016/j.jasc.2019.08.001. Epub 2019 Aug 19.

PMID:
31526696
5.

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.

Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME.

Thyroid. 2019 Aug;29(8):1036-1043. doi: 10.1089/thy.2019.0133.

6.

Extraneural Metastases From a High-Grade Glioma (HGG) With an H3F3A G34R Mutation.

Jethanandani A, Gule-Monroe MK, Chen M, Johnson JM.

Front Oncol. 2019 May 8;9:373. doi: 10.3389/fonc.2019.00373. eCollection 2019.

7.

Incidental detection of oropharyngeal cancer with fluciclovine PET.

Jethanandani A, Chen MM, Gule-Monroe MK, Morrison WH, Lai SY, Johnson JM.

Head Neck. 2019 Aug;41(8):E141-E145. doi: 10.1002/hed.25798. Epub 2019 May 2.

PMID:
31046173
8.

Atypical Alexander disease with dystonia, retinopathy, and a brain mass mimicking astrocytoma.

Machol K, Jankovic J, Vijayakumar D, Burrage LC, Jain M, Lewis RA, Fuller GN, Xu M, Penas-Prado M, Gule-Monroe MK, Rosenfeld JA, Chen R, Eng CM, Yang Y, Lee BH, Moretti PM; Undiagnosed Diseases Network, Dhar SU.

Neurol Genet. 2018 Jul 20;4(4):e248. doi: 10.1212/NXG.0000000000000248. eCollection 2018 Aug. No abstract available.

9.

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.

Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME.

J Immunother Cancer. 2018 Jul 11;6(1):68. doi: 10.1186/s40425-018-0378-y.

10.

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.

Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME.

Thyroid. 2018 Jan;28(1):79-87. doi: 10.1089/thy.2017.0285. Epub 2017 Dec 21.

Supplemental Content

Loading ...
Support Center